Clinical Trial Result Information

Title of Study:
A pilot, open-label, multicentre trial evaluating the safety and effect on viral clearance of increasing the dose of peginterferon alfa-2a in chronic hepatitis C patients infected with difficult-to-treat genotype 1/4/5/6 treated with peginterferon alfa-2a plus ribavirin for 12 weeks without presenting an early virological response

Fast Facts:

Protocol number:	ML18232
Sponsor:	NV Roche SA
Company division:	Pharmaceutical
Product name:	PEGASYS
Generic name:	peginterferon alfa-2a (40KD)
Phase of development:	II
Therapeutic area, approved indication:	Hepatitis C, Chronic
Date of report:	To be Published

Clinical study summary:
Clinical Study Summary: This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.

Click here for the protocol registry listing of this trial.